Elanco director receives 10,314-share annual equity grant

Elanco Animal Health Inc. director equity grant reported A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units.

Rhea-AI Filing Summary

Elanco Animal Health Inc. director equity grant reported

A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open-market purchase. Following this transaction, the director beneficially owns 89,714 shares of Elanco common stock held directly.

The filing notes that this award is part of the regular annual equity compensation provided to non‑employee members of Elanco’s Board of Directors, aligning director pay with shareholder interests through stock-based compensation.

Insider Trade Summary

Grant/Award: 10,314 shares

Grant/Award 1 txn

Insider Kochevar Deborah Turner

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,314	$0.00	$0.00

Holdings After Transaction: Common Stock — 89,714 shares (Direct)

Footnotes (1)

1. F1. Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ELAN report in this Form 4?

A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity grant of 10,314 shares of common stock in the form of deferred stock units on 11/28/2025.

At what price were the ELAN shares granted to the director?

The director received 10,314 Elanco common shares at a stated price of $0, indicating a board compensation grant rather than a market transaction.

How many ELAN shares does the director own after this transaction?

After the grant, the director beneficially owns 89,714 shares of Elanco common stock in direct ownership, as reported in the filing.

What is the relationship of the reporting person to Elanco (ELAN)?

The reporting person is identified as a Director of Elanco Animal Health Inc. and is a non‑employee member of the company’s Board of Directors.

What is the purpose of the 10,314-share grant reported by ELAN?

The 10,314-share grant represents deferred stock units issued as an annual equity award to a non‑employee member of Elanco’s Board of Directors.

Does this ELAN Form 4 involve derivative securities?

The table for derivative securities is included but shows no derivative transactions reported; the disclosed activity relates to non-derivative common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/02/2025 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kochevar Deborah Turner

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		A		10,314	A	$0(1)	89,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Deborah Turner Kochevar	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.